Reported Earnings • Jun 04
Full year 2025 earnings released Full year 2025 results: Revenue: €3.43m (up 16% from FY 2024). Net loss: €1.92m (loss narrowed 34% from FY 2024). Tillkännagivande • Jun 01
Biotechnology Assets, S.A., Annual General Meeting, Jun 29, 2026 Biotechnology Assets, S.A., Annual General Meeting, Jun 29, 2026. Location: gomez acebo & pombo abogados, paseo de la castellana 216, torre realia, madrid., Spain New Risk • May 18
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (€3.1m revenue, or US$3.5m). Market cap is less than US$100m (€17.4m market cap, or US$20.2m). New Risk • Jan 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 6.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (6.7% average weekly change). Minor Risks Revenue is less than US$5m (€3.1m revenue, or US$3.6m). Market cap is less than US$100m (€16.3m market cap, or US$19.5m). Tillkännagivande • May 19
Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025 Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025. Location: hotel melia madrid serrano, calle claudio coello 139., madrid Spain Reported Earnings • May 19
Full year 2024 earnings released Full year 2024 results: Revenue: €2.97m (down 24% from FY 2023). Net loss: €2.92m (down 285% from profit in FY 2023). New Risk • May 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (5.9% average weekly change). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€20.2m market cap, or US$22.7m). New Risk • Apr 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.0% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€21.4m market cap, or US$24.3m). New Risk • Nov 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (€3.4m revenue, or US$3.6m). Market cap is less than US$100m (€23.1m market cap, or US$24.4m). New Risk • Oct 22
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (1.2% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Share price has been volatile over the past 3 months (4.8% average weekly change). Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (€3.9m revenue, or US$4.2m). Market cap is less than US$100m (€19.0m market cap, or US$20.6m). Tillkännagivande • May 21
Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024 Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024. Location: hotel melia madrid serrano, calle claudio coello 139., madrid Spain New Risk • Apr 11
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Revenue has declined by 9.9% over the past year. Minor Risks Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.2m). Market cap is less than US$100m (€21.8m market cap, or US$23.4m). New Risk • Dec 31
New major risk - Revenue and earnings growth Revenue has declined by 9.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (6.5% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (6.8% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.3m). Market cap is less than US$100m (€22.8m market cap, or US$25.2m). New Risk • Oct 29
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.1m). Market cap is less than US$100m (€23.7m market cap, or US$25.0m). Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 02
First half 2021 earnings released The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: (down 100% from 1H 2020). Net income: (up €10.0m from 1H 2020). Profit margin: (up from net loss in 1H 2020). The move to profitability was driven by lower expenses. Is New 90 Day High Low • Feb 08
New 90-day high: €0.84 The company is up 69% from its price of €0.49 on 10 November 2020. The Spanish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period. Is New 90 Day High Low • Jan 18
New 90-day high: €0.67 The company is up 64% from its price of €0.41 on 20 October 2020. The Spanish market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period.